Abstract
The function of many endogenous molecules in all eukaryotic cells depends on their subcellular localisation, being active when localized in one cellular compartment and inactive in another. Translocation or re-localization of mislocalized components in the optimal subcellular site may contribute to the development of novel cancer therapies and to the re-evaluation of conventional treatment. For instance, various agents are able to entrap cytoplasmic anti-apoptotic pathways to the nucleus, thus activating apoptosis. Moreover, amongst the factors identified so far, the optimal location of the tumor suppressor p53 for promoting cell arrest and apoptosis seems to be the nucleus, while the nuclear factor kappa B (NFκB) is desirable to stay in the cytoplasm. Thus, the mechanisms of nuclear translocation of endogenous signaling components, like p53, NFκB and various heat shock proteins (HSPs), may serve as targets for pharmacological intervention, without excluding the possible role of uptake and active transport into the nucleus of extracellular proteins.
Keywords: Anticancer agents, cell cycle, nuclear translocation, stress response, yeast
Current Medicinal Chemistry
Title: Nuclear Translocation During the Cross-Talk Between Cellular Stress, Cell Cycle and Anticancer Agents
Volume: 13 Issue: 11
Author(s): E. Tiligada
Affiliation:
Keywords: Anticancer agents, cell cycle, nuclear translocation, stress response, yeast
Abstract: The function of many endogenous molecules in all eukaryotic cells depends on their subcellular localisation, being active when localized in one cellular compartment and inactive in another. Translocation or re-localization of mislocalized components in the optimal subcellular site may contribute to the development of novel cancer therapies and to the re-evaluation of conventional treatment. For instance, various agents are able to entrap cytoplasmic anti-apoptotic pathways to the nucleus, thus activating apoptosis. Moreover, amongst the factors identified so far, the optimal location of the tumor suppressor p53 for promoting cell arrest and apoptosis seems to be the nucleus, while the nuclear factor kappa B (NFκB) is desirable to stay in the cytoplasm. Thus, the mechanisms of nuclear translocation of endogenous signaling components, like p53, NFκB and various heat shock proteins (HSPs), may serve as targets for pharmacological intervention, without excluding the possible role of uptake and active transport into the nucleus of extracellular proteins.
Export Options
About this article
Cite this article as:
Tiligada E., Nuclear Translocation During the Cross-Talk Between Cellular Stress, Cell Cycle and Anticancer Agents, Current Medicinal Chemistry 2006; 13(11) . https://dx.doi.org/10.2174/092986706776872952
DOI https://dx.doi.org/10.2174/092986706776872952 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Exploiting Anti-Inflammation Effects of Flavonoids in Chronic Inflammatory Diseases
Current Pharmaceutical Design Recent Development in Applications of Important Biopolymer Chitosan in Biomedicine, Pharmaceuticals and Personal Care Products
Current Tissue Engineering (Discontinued) Id-1B, an Alternatively Spliced Isoform of the Inhibitor of Differentiation-1, Impairs Cancer Cell Malignancy Through Inhibition of Proliferation and Angiogenesis
Current Molecular Medicine Possible Biomarkers and Therapeutic Targets for the Management of Cervical Cancer
Current Cancer Therapy Reviews Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Genomics and Public Health Research: Building Public “Goods”? Divergences and Convergences of Views in Four Stakeholder Groups
Current Pharmacogenomics and Personalized Medicine Contemporary Role of Endocrine Treatment in Patients with Localized or Locally Advanced Prostate Cancer: A Review
Current Cancer Therapy Reviews Targeting Therapeutic and Imaging Agents to Folate Receptor Positive Tumors
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Pathogenetic Mechanisms of CLL - A Target in Therapy)
Current Cancer Drug Targets Preclinical Evidence on the Anticancer Properties of Food Peptides
Protein & Peptide Letters (Review Article) Screening for Disease-Markers and Investigating Drug Effects by Proteome Profiling: Can it Meet Expectations?
Combinatorial Chemistry & High Throughput Screening Steroid Hormone Binding Receptors: Application of Homology Modeling, Induced Fit Docking, and Molecular Dynamics to Study Structure- Function Relationships
Current Topics in Medicinal Chemistry Targeting the Expression of Anti-Apoptotic Proteins by Antisense Oligonucleotides
Current Drug Targets Subungueal Haemorrhages Following Docetaxel (Taxotere) Treatment
Current Drug Safety Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Current Drug Metabolism Current Overview on the Usage of Poly(ADP-ribose)polymerase (PARP) Inhibitors in Treating Cancer
Clinical Cancer Drugs A Role for SNX1 in the Regulation of EGF-Dependent Phosphorylated EGFR Endocytosis Via the Early/Late Endocytic Pathway in a Gefitinib-Sensitive Human Lung Cancer Cells
Current Signal Transduction Therapy Functional Neuroimaging of Stimulation by Music Using Positron Emission Tomography
Current Medical Imaging Graphical Abstracts:
Current Radiopharmaceuticals Therapeutic Strategies to Target TGF-β in the Treatment of Bone Metastases
Current Pharmaceutical Biotechnology